Abstract: This steel sheet for hot-stamping includes: a base steel sheet having a predetermined chemical composition; and a galvanized layer formed on a surface of the base steel sheet, in which a microstructure at a position at ¼ depth which is in a range of ? to ? of a sheet thickness in a sheet thickness direction from the surface of the base steel sheet contains, in volume fraction, ferrite: 20% to 95% and pearlite: 5% to 80%, the remaining structure including bainite, the galvanized layer has a coating amount of 90 g/m2 or more, and when the maximum value of the B content in the galvanized layer is Bps and the B content at the position at ¼ depth of the base steel sheet is Bqs, Bps is 1.2 times or more Bqs.

Abstract: Compounds and methods for activating Nrf2 by inhibiting KEAP1.

Abstract: Disclosed are compounds of Formula (I): or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W are as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a proliferative disease, such as cancer.

Abstract: This hot-dip galvanized steel sheet includes: a steel sheet; a boundary layer provided on the steel sheet; and a hot-dip galvanized layer provided on the boundary layer, in which the steel sheet has a predetermined chemical composition, in a region between a surface of the steel sheet and a depth of 25 ?m from the surface of the steel sheet, an average grain size exceeds 4.0 ?m, in a region between a position of 50 ?m from the surface of the steel sheet and a position of 100 ?m from the surface of the steel sheet, an area ratio of unrecrystallized ferrite is 50% or more, and in the hot-dip galvanized layer, a maximum value of a C concentration is 0.05 mass % or more.

Abstract: Disclosed herein are compounds selective for JAK1, pharmaceutical compositions comprising said compounds, and methods of using said compounds.

Abstract: Compounds and methods for inhibiting Nrf2 by activating KEAP1.

Abstract: Disclosed are compounds of Formula (I): or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W are as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a proliferative disease, such as cancer.

Abstract: Disclosed are compounds of Formula (I): or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W are as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a proliferative disease, such as cancer.

Abstract: This hot-dip galvanized steel sheet includes: a steel sheet; a boundary layer provided on the steel sheet; and a hot-dip galvanized layer provided on the boundary layer, in which the steel sheet has a predetermined chemical composition, in a region between a surface of the steel sheet and a depth of 25 ?m from the surface of the steel sheet, an average grain size exceeds 4.0 ?m, in a region between a position of 50 ?m from the surface of the steel sheet and a position of 100 ?m from the surface of the steel sheet, an area ratio of unrecrystallized ferrite is 50% or more, and in the hot-dip galvanized layer, a maximum value of a U concentration is 0.05 mass % or more.

Abstract: A hot-dip zinc-plated steel sheet includes a steel sheet, a boundary layer that is provided on a surface of the steel sheet, and a hot-dip zinc-plated layer that is provided on a surface of the boundary layer. In a surface layer region of the steel sheet, an average grain size is 4.0 ?m or less and a standard deviation of grain sizes is 2.0 ?m or less. In the boundary layer, a maximum Al concentration is 0.30 mass % or more.

Abstract: A hot-stamping formed body includes a steel sheet and a zinc-plated layer that is provided on the steel sheet. The steel sheet has a predetermined chemical composition, and an area % of martensite is 90% or more in microstructure at a position corresponding to ¼ of a sheet thickness of the steel sheet from a surface of the steel sheet in a sheet thickness direction. The zinc-plated layer includes a F phase and a Fe—Zn solid solution, and a cross-sectional area ratio of voids present in the zinc-plated layer is 15.0% or less.

Abstract: Disclosed herein are isoindolinone compounds and methods for binding cereblon and for modulating cereblon neosubstrates. The isoindolinone compounds can have a structure of Formula (I).

Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.

Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.

Abstract: The fatigue strength of a lap-welded joint, wherein an overlapping portion of a first steel material and an overlapping portion of a second steel material overlap with each other, and an edge portion of the first steel material is welded to a front face of the second steel material with a weld zone extending along the edge portion, is improved. First, when a direction perpendicular to an extending direction X of the weld zone and parallel to a front face of the second steel material is defined as a reference direction Y, the lap-welded joint is restrained from moving in the reference direction Y, and the first steel material and the second steel material are restrained from moving in their sheet-thickness directions. In this state, a portion of the second steel material is heated such that a melted portion is formed in the portion of the second steel material.

Abstract: The present invention provides 5-HT3 receptor antagonists of Formula (I): which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Abstract: Disclosed is a compound of Formula 1, and a pharmaceutically acceptable salt thereof. This disclosure also relates to materials and methods for preparing the compound of Formula 1, to pharmaceutical compositions which contain it, and to its use for treating diseases, disorders, and conditions associated with GPR6.

Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.

Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.

Abstract: A control unit of an aircraft includes a computer that predicts the current position of a wingman aircraft based on a temporal change in wingman-aircraft position information indicating the position of the wingman aircraft; an antenna selector that selects, from among multiple antennas, an antenna with which the elongation ?t with respect to the center axis of the antenna at the predicted current position of the wingman aircraft predicted by the computer falls within a coverage angle ?; and a beam controller that executes communication with the wingman aircraft via the antenna selected by the antenna selector. Thus, the control unit of the aircraft can select an optimal antenna for communication with the wingman aircraft from among the multiple antennas.